A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
The purpose of this study is to compare the effects, good and/or bad, of the study drug PCI-32765 (Ibrutinib) with bendamustine and rituximab on participants with newly diagnosed Mantle Cell Lymphoma.
Newly diagnosed Mantle Cell Lymphoma
Participant is 65 years of age or older
Newly diagnosed with Mantle Cell Lymphoma
No prior therapies for Mantle Cell Lymphoma
65 - 99
Healthy Volunteers Needed
Duration of Participation
Approximately 6.5 years, with long-term follow-up.
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
Janssen Research & Development LLC